HIV trial has completed its recruitment target. KONCERT is
examining alternative dosing for a type of antiretroviral
(anti-HIV) medicine called Kaletra that is currently used in
children. The KONCERT team want to thank all participants, families
and research teams that have contributed to this achievement.
A total number of 173 participants from
Thailand, South America and Europe have been enrolled and the study
is now closed to recruitment.
The first aim of KONCERT is to find out
whether taking Kaletra once-daily rather than twice-daily is safe
and effective in children. It is very important to take
antiretroviral medicines every day but it can be very difficult to
give them to children several times per day. If medicines can be
taken safely once-daily, this may make them easier to give.
The second aim of KONCERT is to get more information about the
correct dose of Kaletra to give to children. This is done by
measuring the level of the medicine in the child’s blood. This
information is needed because a smaller Kaletra tablet for children
has recently been approved in many countries using the body surface
area calculation but we would like to check that dosing by weight
band, which is less prone to error, can also be used.
All participants will now be followed-up for
48 weeks. Final results of the trial will be available in autumn